Mondor disease in a patient with psoriasis treated with an anti-interleukin 12/interleukin 23 investigational drug.
Hirano
Stefanie A
SA
Mason
Ashley R
AR
Warthan
Molly M
MM
Pariser
Robert J
RJ
D001707:Biopsy, Needle; D015507:Drugs, Investigational / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007279:Injections, Subcutaneous; D018664:Interleukin-12 / Q000009:adverse effects* / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D053759:Interleukin-23 / Q000009:adverse effects* / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D040521:Subcutaneous Tissue / Q000098:blood supply / Q000473:pathology; D035441:Thoracic Wall; D013924:Thrombophlebitis / Q000139:chemically induced* / Q000473:pathology; D016896:Treatment Outcome
D015507:Drugs, Investigational; D053759:Interleukin-23; D018664:Interleukin-12